BCL2 and non-small cell lung carcinoma: DTP cells emerging after challenge with EGFR TKIs have also been reported to be dependent on the suppression of apoptosis [137], and the non-selective BCL-2/Bcl-xL inhibitor ABT-263 is being trialed in combination with osimertinib in EGFR TKI-resistant NSCLC patients (NCT02520778).